Patents Issued in June 7, 2016
-
Patent number: 9358213Abstract: The present invention relates to pharmaceutical compositions of duloxetine or pharmaceutically acceptable salts thereof, and processes for their preparation.Type: GrantFiled: April 19, 2008Date of Patent: June 7, 2016Assignee: WOCKHARDT LIMITEDInventors: Girish Kumar Jain, Chandrashekhar Kandi, Vishwanath Nande
-
Patent number: 9358214Abstract: A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.Type: GrantFiled: June 2, 2003Date of Patent: June 7, 2016Assignee: ADARE Pharmaceuticals, Inc.Inventors: Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh
-
Patent number: 9358215Abstract: This application provides a high throughput method of making nanoparticles that utilizes plates comprising wells (e.g., 96-well plates).Type: GrantFiled: September 29, 2014Date of Patent: June 7, 2016Assignee: BIND THERAPEUTICS, INC.Inventor: David M. Dewitt
-
Patent number: 9358216Abstract: Methods and formulations for infusing bioavailable resveratrol tinctures into food, beverage, cosmetic or drug products with minimal effect on the alcohol by volume of the product is provided. A resveratrol tincture includes an amount of trans-resveratrol mixed with a solvent of pure, or majority by weight, ethanol. The tincture is added to various food and beverages to make a bioavailable amount of trans-resveratrol to be absorbed and metabolized by the body providing demonstrated health benefits.Type: GrantFiled: July 31, 2015Date of Patent: June 7, 2016Assignee: Heart Healthy Spirits, LLCInventors: Jeffrey J Keaffaber, Kim A. Popejoy
-
Patent number: 9358217Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (TG), total cholesterol (TC) and low density lipoprotein (LDL) in human subjects.Type: GrantFiled: November 13, 2014Date of Patent: June 7, 2016Assignee: MediciNova, Inc.Inventor: Kazuko Matsuda
-
Patent number: 9358218Abstract: The present invention relates to use of a tall oil fatty acid which is modified by saponification in enhancing rumen fermentation and/or lowering rumen methane production.Type: GrantFiled: May 14, 2013Date of Patent: June 7, 2016Assignee: Hankkija OyInventors: Juhani Vuorenmaa, Hannele Kettunen
-
Patent number: 9358219Abstract: A pharmaceutical composition comprises an active ingredient dissolved in an essentially non-aqueous carrier system comprising volatile and non-volatile components, in which the volatile component comprises a volatile non-solvent for the active ingredient and a volatile solvation additive for the non-solvent and the non-volatile component comprises a non-volatile non-solvent and optionally a non-volatile solvent for the active ingredient, the volatile and non-volatile non-solvents comprising silicone fluids of respectively different viscosity.Type: GrantFiled: November 10, 2010Date of Patent: June 7, 2016Assignee: Futura Medical Developments LimitedInventor: Adrian Francis Davis
-
Patent number: 9358220Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.Type: GrantFiled: January 28, 2015Date of Patent: June 7, 2016Assignee: THESAN PHARMACEUTICALS, INC.Inventor: Jean Hilaire Saurat
-
Method for manufacturing composition for lowering blood lipid and elevating high-density lipoprotein
Patent number: 9358221Abstract: The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; the composition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a Monascus fermented product with acetone for three times; elevating the concentration of the Monascus fermented product by a process of decompress concentration; and extracting the monascin and the ankaflavin from the Monascus fermented product with a silica gel column chromatography, a Sephadex LH-20 column chromatography, the silica gel column chromatography, and a preparative high performance liquid chromatography sequentially.Type: GrantFiled: March 7, 2013Date of Patent: June 7, 2016Assignee: SUNWAY BIOTECH CO., LTD.Inventors: Tzu-Ming Pan, Chun-Lin Lee, Cheng-Lun Wu -
Patent number: 9358222Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.Type: GrantFiled: November 20, 2013Date of Patent: June 7, 2016Assignee: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
-
Patent number: 9358223Abstract: An implantable drug depot useful for preventing, reducing or treating bleeding at a surgical site beneath the skin in a patient is provided. The implantable drug depot comprises a therapeutically effective amount of clonidine or a pharmaceutically acceptable salt thereof, and at least one biodegradable polymer. The drug depot is capable of releasing clonidine or a pharmaceutically acceptable salt thereof over a period of at least three days.Type: GrantFiled: April 9, 2014Date of Patent: June 7, 2016Assignee: Warsaw Orthopedic, Inc.Inventor: Vanja Margareta King
-
Patent number: 9358224Abstract: Pharmaceutical formulations to be administered by pressurized metered dose inhalers (pMDIs), comprising a compound of general formula (I) may be used for the treatment and/or prevention of inflammatory or obstructive airway diseases.Type: GrantFiled: August 2, 2011Date of Patent: June 7, 2016Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Sauro Bonelli, Elena Losi, Enrico Zambelli
-
Patent number: 9358225Abstract: Ataxia-telangiectasia (A-T) is a progressive degenerative disorder that results in major neurological disability. In A-T patients, necropsy has revealed atrophy of all cerebellar cortical layers with extensive Purkinje and granular cell loss. We have previously identified an increase in phospho-p38MAPK levels, which was accompanied by downregulation of Bmi-1 and upregulation of p21, as key components of the mechanism causing defective proliferation of neural stem cells (NSCs) isolated from subventricular zone (SVZ) of Atm-null mice. Our results demonstrate that restoration of NSCs by pharmacologic inhibition of p38MAPK signaling has the potential to treat neurological defects of A-T. This study provides new insights into the therapeutic strategy targeting NSCs rather than replacing impaired neurons not only for A-T, but for other neurodegenerative disorders as well.Type: GrantFiled: March 17, 2014Date of Patent: June 7, 2016Assignee: Bach Pharma, Inc.Inventor: Paul K. Y. Wong
-
Patent number: 9358226Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogs of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.Type: GrantFiled: March 6, 2012Date of Patent: June 7, 2016Assignees: Emory University, The United States of America as represented by the Department of Veterans AffairsInventor: Jack L. Arbiser
-
Patent number: 9358227Abstract: Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives are disclosed. Specifically, the 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, are protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification.Type: GrantFiled: December 1, 2014Date of Patent: June 7, 2016Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Xin Li, Bin Wang
-
Patent number: 9358228Abstract: Combinations of netupitant and palonosetron, and methods of using such combinations to treat various pain states and irritable bowel syndrome, are provided.Type: GrantFiled: October 10, 2012Date of Patent: June 7, 2016Assignee: HELSINN HEALTHCARE SAInventors: Claudio Pietra, Sergio Cantoreggi
-
Patent number: 9358229Abstract: Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PI3K/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy.Type: GrantFiled: August 10, 2012Date of Patent: June 7, 2016Assignees: Novartis Pharma AG, Incyte CorporationInventors: Alessandro M. Vannucchi, Costanza Bogani, Niccolo Bartalucci
-
Patent number: 9358230Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.Type: GrantFiled: February 3, 2016Date of Patent: June 7, 2016Assignee: Purdue Pharma L.P.Inventors: Frank S. Caruso, Huai-Hung Kao
-
Patent number: 9358231Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.Type: GrantFiled: November 24, 2014Date of Patent: June 7, 2016Assignees: Dana-Farber Cancer Institute, Inc., University of MiamiInventors: Nathanael Gray, Hwan Geun Choi, Xianming Deng, Jianming Zhang, Izidore Lossos
-
Patent number: 9358232Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.Type: GrantFiled: April 16, 2014Date of Patent: June 7, 2016Assignee: Signal Pharmaceuticals, LLCInventors: Kristen Mae Hege, Rajesh Chopra
-
Patent number: 9358233Abstract: The present invention relates to the use of BI 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising the administration of a high dose of BI 6727 according to a specific dosage schedule, optionally in combination with cytarabine.Type: GrantFiled: November 16, 2011Date of Patent: June 7, 2016Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Tillmann Taube, Gerd Munzert, Dorothea Rudolph
-
Patent number: 9358234Abstract: This invention provides methods for preparing novel mammalian multipotent stem cells (MSCs), compositions thereof, and methods of preparing and administering the cells.Type: GrantFiled: June 5, 2012Date of Patent: June 7, 2016Assignee: The Board of Trustees of the University of IllinoisInventors: Kiminobu Sugaya, Tingyu Qu, Ankur V. Vaghani, Christopher Brannen, Hojoong M. Kim, Jose S. Pulido, Xiajing Dong
-
Patent number: 9358235Abstract: The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.Type: GrantFiled: March 13, 2013Date of Patent: June 7, 2016Assignee: Plexxikon Inc.Inventors: Gideon Bollag, Klaus-Peter Hirth, Prabha N. Ibrahim, Paul Lin, Brian West
-
Patent number: 9358236Abstract: The present invention relates to a combination of an allosteric mTOR inhibitor and a catalytic mTOR inhibitor for use in the prevention or treatment of neurodegenerative diseases, for example Huntington's Disease, and products and pharmaceutical compositions comprising such a combination for use in the prevention or treatment of such neurodegenerative diseases.Type: GrantFiled: February 14, 2012Date of Patent: June 7, 2016Assignee: Novartis AGInventors: Leon Murphy, Jvan Galimberti
-
Patent number: 9358237Abstract: Disclosed are noribogaine compositions comprising a very high level of the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and not more than 0.5 wt % of ibogaine relative to the total amount of noribogaine.Type: GrantFiled: July 22, 2011Date of Patent: June 7, 2016Assignee: DEMERX, INC.Inventors: Robert M. Moriarty, Deborah C. Mash
-
Patent number: 9358238Abstract: A method of enhancing the performance of chicken comprising administering zilpaterol to the chicken wherein the concentration of zilpaterol is from about 1 ppm to about 13 ppm and is administered every day for a period of about 7 to about 21 days.Type: GrantFiled: April 1, 2015Date of Patent: June 7, 2016Assignee: Intervet Inc.Inventor: John A. Rogers
-
Patent number: 9358239Abstract: The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models. The results have demonstrated how NiSOD-like compounds are likely to work in suppressing abnormal protein aggregation, recovering cell viability, increasing mature neuron number and neurite outgrowth length and protecting dopaminergic cells by reducing oxidative stress or reactive oxygen species in brain tissues.Type: GrantFiled: January 26, 2015Date of Patent: June 7, 2016Assignee: National Taiwan Normal UniversityInventors: Way-Zen Lee, Guey-Jen Lee, Hsiu-Mei Hsieh, Chien-Wei Chiang, Bin Huang, Yaw-Syan Fu, Yun-Ming Wang
-
Patent number: 9358240Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: November 12, 2009Date of Patent: June 7, 2016Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Patent number: 9358241Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.Type: GrantFiled: June 6, 2014Date of Patent: June 7, 2016Assignee: LIPOCINE INC.Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V Patel
-
Patent number: 9358242Abstract: Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway.Type: GrantFiled: March 1, 2010Date of Patent: June 7, 2016Assignee: Prelief Inc.Inventors: Alan E. Kligerman, Margaret T. Weis
-
Patent number: 9358243Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.Type: GrantFiled: September 28, 2012Date of Patent: June 7, 2016Assignee: ETH ZURICHInventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
-
Patent number: 9358244Abstract: The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases, such as leishmaniasis, chagas and malaria, and cancer both in humans and animals. Specifically, the present invention relates to a solid dosage form comprising: 6 to 25 weight % of the solid dosage form oleyl phosphocholine; 20 to 35 weight % of the solid dosage form lactose; 35 to 50 weight % of the solid dosage form cellulose; 5 to 20 weight % of the solid dosage form croscarmellose; 1 to 10 weight % of the solid dosage form hydroxypropylmethyl cellulose; and 0.05 to 1 weight % of the solid dosage form of a lubricant.Type: GrantFiled: November 21, 2011Date of Patent: June 7, 2016Assignee: Oblita Therapeutics BVBAInventors: Frans Herwig Jansen, Bruno Jansen
-
Patent number: 9358245Abstract: Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.Type: GrantFiled: April 16, 2014Date of Patent: June 7, 2016Assignee: Cedars-Sinai Medical CenterInventors: Mark Pimentel, Henry C. Lin
-
Patent number: 9358246Abstract: A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.Type: GrantFiled: September 15, 2014Date of Patent: June 7, 2016Assignees: Microbial Chemistry Research Foundation, The University of TokyoInventors: Ryoichi Matsuda, Masataka Shiozuka, Akira Wagatsuma, Yoshikazu Takahashi, Daishiro Ikeda, Yoshiaki Nonomura, Masafumi Matsuo, Atsushi Nishida
-
Patent number: 9358247Abstract: The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.Type: GrantFiled: September 3, 2014Date of Patent: June 7, 2016Assignee: Oncology Research International LimitedInventors: Michael John Story, Kenneth Michael Wayte
-
Patent number: 9358248Abstract: Oligonucleotide analogs are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2?-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogs rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogs can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogs and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogs, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.Type: GrantFiled: May 14, 2013Date of Patent: June 7, 2016Assignee: ASTEX PHARMACEUTICALS, INC.Inventors: Pasit Phiasivongsa, Sanjeev Redkar
-
Patent number: 9358249Abstract: In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.Type: GrantFiled: November 18, 2009Date of Patent: June 7, 2016Assignee: The Regents of the University of CaliforniaInventors: Jing Huang, Rui Hao, Brett Eugene Lomenick, Nao Jonai, Simon Diep
-
Patent number: 9358250Abstract: Provided herein are therapies for the treatment of pathological conditions, such as cancer, and method of using SCD1 antagonists.Type: GrantFiled: October 12, 2012Date of Patent: June 7, 2016Assignee: Genentech, Inc.Inventors: Avi Ashkenazi, Xiangnan Du, Jing Qing
-
Patent number: 9358251Abstract: The invention relates to a method for dissolving the components of gel forming materials suitable for use in wound care comprising the steps of admixing said components with an ionic liquid. The ionic liquid may be selected from the group of tertiary amine N-oxides, N,N-dimethyl formamide/nitrogen tetroxide mixtures, dimethyl sulphoxide/paraformaldehyde mixtures and solutions of limium chloride in N,N-dimethyl acetamide or N-methyl pyrrolidone.Type: GrantFiled: November 22, 2007Date of Patent: June 7, 2016Assignee: CONVATEC TECHNOLOGIES INC.Inventors: David Kershaw, Simon Adams
-
Patent number: 9358252Abstract: Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.Type: GrantFiled: September 27, 2013Date of Patent: June 7, 2016Assignee: MOMENTA PHARMACEUTICALS, INC.Inventors: Mallikarjun Sundaram, Takashi Kei Kishimoto, Sucharita Roy
-
Patent number: 9358254Abstract: A method of treating or preventing Helicobacter pylori infection in a subject, includes the step of orally administering to the subject a composition including a carbonaceous material that has a pore defined therein which has a radius of more than 0 nm but less than 2.5 nm; and from 0.001-15% by weight, based on weight of the carbonaceous material, of an active particle coated that is on the carbonaceous material and that is made of a material selected from the group consisting of silver, gold, aluminum, zinc, copper, and titanium dioxide.Type: GrantFiled: September 30, 2013Date of Patent: June 7, 2016Assignee: FENG CHIA UNIVERSITYInventor: Tse-Hao Ko
-
Patent number: 9358255Abstract: The invention is directed to a method for isolating stromal cells to form a therapeutic composition; and administering said therapeutic composition to the subject. A further embodiment of the invention is directed to therapeutic compositions comprising isolated stromal cells.Type: GrantFiled: October 8, 2013Date of Patent: June 7, 2016Assignee: SpineSmith Partners, L.P.Inventors: Kevin Dunworth, Richard J. Kana, Theodore Sand, Matthew Murphy
-
Patent number: 9358256Abstract: A gap-patterned wound dressing, including a patterned foam structure having a gap patterned side and a non-gap patterned side, wherein the gap patterned side includes a pattern of foam gaps disposed between foam areas dosed with honey, where the pattern of foam gaps is formed by the honey dosed areas; and wherein a wound in contact with the gap patterned side discharges an exudate which substantially collects in the individual ones of the foam gaps causing honey in the individual ones of the honey dosed areas to be substantially dispersed throughout a wound treatment zone.Type: GrantFiled: July 11, 2013Date of Patent: June 7, 2016Assignee: Links Medical Products, Inc.Inventors: Greg Devenish, Howard Kenneth Payne
-
Patent number: 9358257Abstract: A serum resistin level reducing agent that comprises a cell wall disrupted product of a Chlorella pyrenoidos, and that reduces a serum resistin level, as an agent for oral administration. A food or beverage composition for reducing a serum resistin level that comprises a cell wall disrupted product of a Chlorella pyrenoidos, and that reduces a serum resistin level. A method of reducing a serum resistin level by applying a cell wall disrupted product of a chlorella for oral administration. A use of a cell wall disrupted product of a chlorella for oral administration for reducing a serum resistin level.Type: GrantFiled: July 10, 2014Date of Patent: June 7, 2016Assignee: SUN CHLORELLA CORP.Inventors: Hiroshige Itakura, Tetsuaki Nakayama, Ryo Matoba
-
Patent number: 9358258Abstract: The present invention relates to a novel bacteriophage having an E. coli-specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E. coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an active ingredient, a sanitizer or cleaner comprising the bacteriophage as an active ingredient, and a method for treating colibacillosis using the bacteriophage. The novel bacteriophage of the present invention has a specific bactericidal activity against pathogenic E. coli, and excellent acid- and heat-resistance. Therefore, the novel bacteriophage can be used for the prevention or treatment of swine colibacillosis, which is an infectious disease caused by pathogenic E. coli, and can also be widely used in animal feed additive compositions, sanitizers, and cleaners.Type: GrantFiled: November 14, 2012Date of Patent: June 7, 2016Assignee: CJ CHEILJEDANG CORPORATIONInventors: Jae Won Kim, Young Wook Cho, Eun Mi Shin, Young Sa Kim, Si Yong Yang
-
Patent number: 9358259Abstract: A process and apparatus for extracting cannabinoids from cannabis plant material plant material and for transporting low concentrations of cannabinoids in a solution of solvent includes at least a solvent tank, a hopper, and one or more pumps. A plurality of valves may also be incorporated into the invention. Plant material may be soaked, washed, and/or rinsed with a solvent that extracts essential elements from cannabis plant matter. The process minimally includes filling a hopper with plant mater, moving solvent from a solvent tank to the hopper, and moving solvent back to the solvent tank after an extraction. Repeating this process a plurality of times with new plant material increases the concentration cannabinoids in the solvent tank after each time the process is performed.Type: GrantFiled: March 20, 2012Date of Patent: June 7, 2016Inventors: Andrew David Hospodor, Robert James Rapp
-
Patent number: 9358260Abstract: The present invention relates to a process for obtaining a Labisia pumila water extract comprising the steps of: obtaining an extract from dried Labisia pumila plant material using water extraction, filtering the extract to obtain filtrate and Labisia pumila plant material residue, re-extracting the Labisia pumila residue using water extraction, centrifuging the Labisia pumila extracts to obtain a supernatant, characterized in that, the Labisia pumila plant material includes leaves and roots in a ratio of 3:2 by weight and ratio of the dried plant material to water used in the water extraction process is 1:10 by weight, wherein the yield obtained from initial extraction is 7% to 8% and the extra yield obtained from re-extraction is 33% to 38% and the total yield obtained from the extraction is 10% to 12%.Type: GrantFiled: February 5, 2013Date of Patent: June 7, 2016Assignee: PHARMANIAGA BHDInventors: Defri bin Zulkarnaini, Noridayu Che Ani, Miau Ching Ho, Visweswaran Navaratnam, Venkatesh Gantala
-
Patent number: 9358261Abstract: An Alternative ACT composition consisting of natural botanical active ingredients, all of which are GRAS (generally regarded as safe by the FDA). The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives, berberine, capsaicin, and papaya extract. The four active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for the treatment and prevention of chikungunya.Type: GrantFiled: November 5, 2015Date of Patent: June 7, 2016Assignee: U.S. Phytotherapy, Inc.Inventor: Bob Rosen
-
Patent number: 9358262Abstract: A method of treating or preventing diabetes or obesity that comprises administering an antioxidant-enriched composition produced by fermenting fruit extracts with the bacteria Serratia vaccinii. The antioxidant-enriched composition is capable of decreasing plasma glucose levels, increasing circulating adiponectin levels and decreasing hyperphagia in a subject.Type: GrantFiled: August 14, 2009Date of Patent: June 7, 2016Assignee: University of OttawaInventors: Chantal Matar, Pierre S. Haddad
-
Patent number: 9358263Abstract: Personal care composition comprising at least one extract selected from the group consisting of extracts of Terminalia bellerica, Butea monosperma, Mallotus philippinensis, Anogeissus latifolia, Innula racemosa, Ficus benghalensis, Nerium indicum, Psoralea corylifolia, Acacia catechu, Abies pindrow, Cedrus deodara, Emblica officinalis, Moringa oleifera, Glycyrrhiza glabra, and mixtures thereof, and a dermatologically acceptable carrier. Additionally or alternatively, the composition may comprise 2-hexyldecanol.Type: GrantFiled: February 28, 2008Date of Patent: June 7, 2016Assignee: The Procter & Gamble CompanyInventors: Cheri Lynn Millikin, Laura Jackson Goodman, Donald Lynn Bissett, Larry Richard Robinson, Rosemarie Osborne